Background: Transpupillary thermotherapy is a new and most promising treatment modality for up to medium-sized choroidal melanoma at the posterior pole. We analysed the results of conventional ruthenium-106 brachytherapy in these special tumour subgroup.
Patients And Methods: Results of ruthenium-106 brachytherapy (radioactive dose to the tumour apex 150 Gy) in a series of 52 eyes with primary malignant choroidal melanoma (posterior to the equator, thickness = 4.5 mm, base diameter = 12 mm) were evaluated retrospectively. Mean tumour thickness was 3.2 mm. The posterior tumour margin was in 20 eyes = 2 optic disc diameter away from the macula and in 10 eyes = 2 optic disc diameter away from the optic disc. Follow-up was 3 - 9 years (median 5.6 years).
Results: Tumour control was achieved in 48 eyes (92 %): completely flattened scar in 71 %, residual prominence = 2 mm in 16 %, no apparent response (but high reflectivity in ultrasonographic examination) in 5 %. 4 eyes were removed because of tumour regrowth (3 x) or secondary glaucoma (1 x). Visual outcome mainly depends on tumour location in respect of fovea and the optic nerve. Because 40 % of the eyes developed radiation maculopathy and 20 % radiation optic neuropathy 25 eyes (48 %) reached a final visual acuity = 0.2. 40 eyes (77 %) revealed a visual loss of at least 2 lines. Two patients died of liver metastases.
Conclusion: In posterior choroidal melanoma ruthenium-brachytherapy achieved an excellent rate of tumour control, but functional results were disappointing because of late radiation sideeffects. Transpupillary thermotherapy as an adjunct to ruthenium plaque radiotherapy may be able to reduce the radioactive dose.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-2002-30654 | DOI Listing |
Ocul Oncol Pathol
December 2024
Cairo University Ocular Oncology Service, Department of Ophthalmology, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Ocul Oncol Pathol
December 2024
Ophthalmology Department, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Introduction: Clear evidence for the best clinical management of uveal melanoma is lacking in some areas. Therefore, reports on expert opinions in the field can be valuable.
Methods: A questionnaire comprising 10 questions was distributed to potential participants of the 58th Ophthalmic Oncology Group Meeting in Stockholm, Sweden, in June 2024.
Brachytherapy
November 2024
The Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Road no 2, Banjara Hills, Hyderabad, 500034 India.
Purpose: To describe the clinical presentation and treatment outcomes of patients undergoing Ruthenium-106 (Ru) plaque brachytherapy as salvage treatment for retinoblastoma (RB) following intravenous chemotherapy (IVC).
Methods: Retrospective chart review of 44 eyes of 42 patients. The indications for plaque brachytherapy included solid tumor recurrence (n=20; 45%), solid tumor residual (n=16; 36%), new subretinal seeds (n=5; 12%), and new solid tumor (n=3; 7%).
Cancers (Basel)
October 2024
Department of Ophthalmology, National University Health System, Singapore 119228, Singapore.
Ocul Oncol Pathol
September 2024
Cairo University Ocular Oncology Service, Department of Ophthalmology, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!